O
COGT icon

OrbiMed’s Cogent Biosciences COGT Stock Holding History

OrbiMed’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Sell
322,100
-48,900
-13% -$1.81M 0.25% 75
2025
Q4 		$13.2M Buy
+371,000
New +$10.4M 0.27% 72
2021
Q1 		– Sell
-655,000
Closed -$7.36M – 165
2020
Q4 		$7.36M Buy
+655,000
New +$7.2M 0.06% 132

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

OrbiMed's COGT Position: Q1 2026 in Review

OrbiMed reduced its Cogent Biosciences (COGT) stake by 13% in Q1 2026, selling an estimated $1.81M and leaving 322,100 shares worth $12.4M. The position accounts for 0.25% of the portfolio, ranked #75.

OrbiMed first reported a position in COGT in Q4 2020 and has held it in 3 quarters since. The position peaked at $13.2M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • OrbiMed held 322,100 shares of Cogent Biosciences worth $12.4M as of Q1 2026.
  • OrbiMed sold 48,900 Cogent Biosciences shares in Q1 2026, an estimated $1.81M.
  • Cogent Biosciences made up 0.25% of OrbiMed's portfolio in Q1 2026, its #75 holding.
  • OrbiMed first reported a position in Cogent Biosciences in Q4 2020 and has held it in 3 quarters since.
  • OrbiMed's Cogent Biosciences position peaked at $13.2M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.